AG-01 + AG-05

AG-01 + AG-05 refers to a combination therapy involving two distinct research compounds likely in preclinical or early clinical development. AG-01 is a monoclonal antibody developed by A&G Pharmaceutical targeting progranulin (also known as GP88 or PGRN), a growth factor implicated in tumorigenesis and drug resistance in various cancers, particularly triple-negative breast cancer. AG-01 has demonstrated preclinical efficacy in inhibiting proliferation and migration of breast cancer cells by blocking PGRN/GP88 signaling and associated kinases (such as Src, AKT, and ERK). The mechanism, indications, and details for AG-05 are not identified in available sources, but the use of "+" implies a combination intended to achieve multi-target synergy, possibly to improve therapeutic selectivity, efficacy, or overcome resistance seen with single agents. No regulatory approvals or advanced clinical development for this specific combination are reported[2][3][1].

Other names

AG-01 + AG-05